Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free TXMD Stock Alerts

TherapeuticsMD (TXMD) Financials

TherapeuticsMD logo
$2.04 +0.10 (+5.15%)
As of 07/16/2026 04:00 PM Eastern
Compare
Annual Income Statements for TherapeuticsMD

Annual Income Statements for TherapeuticsMD

This table shows TherapeuticsMD's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -85 -90 -77 -133 -176 -184 -172 112 -10 -2.18 -0.57
Consolidated Net Income / (Loss)		 -85 -90 -77 -133 -176 -184 -172 112 -10 -2.18 -0.57
Net Income / (Loss) Continuing Operations		 -85 -90 -77 -133 -176 -184 -79 1.07 -7.70 -2.31 -0.65
Total Pre-Tax Income 		-85 -90 -77 -133 -176 -184 -79 1.07 -7.74 -2.34 -0.65
Total Operating Income		 -85 -90 -78 -130 -151 -156 -80 1.19 -8.52 -6.11 -4.39
Total Gross Profit		 16 15 14 13 43 49 1.17 69 1.30 1.76 3.02
Total Revenue		 20 19 17 16 50 65 2.57 70 1.30 1.76 3.02
Operating Revenue		 20 19 17 16 50 65 2.57 - 1.30 1.76 3.02
Total Cost of Revenue		 4.51 4.19 2.64 2.74 6.34 16 1.40 1.40 0.00 0.00 0.00
Total Operating Expenses		 101 105 92 144 195 204 81 67 9.83 7.87 7.41
Selling, General & Admin Expense		 29 51 58 116 60 77 81 57 8.90 6.10 6.85
Depreciation Expense		 0.06 0.13 0.21 0.29 - - - 1.19 0.92 0.51 0.38
Impairment Charge		 - - - - - - - - 0.00 1.27 0.18
Total Other Income / (Expense), net		 0.11 0.38 0.70 -2.40 -25 -28 0.27 0.00 0.78 3.77 3.74
Interest & Investment Income		 - - - - - - - - - 0.14 0.14
Other Income / (Expense), net		 0.10 0.37 0.70 2.28 2.50 0.60 0.27 - 0.78 3.63 3.60
Income Tax Expense		 - - 0.00 0.00 0.00 0.00 0.00 0.00 -0.04 -0.03 0.00
Net Income / (Loss) Discontinued Operations		 - - - - - - -93 111 -2.58 0.13 0.08
Basic Earnings per Share		 ($0.49) ($0.46) ($0.37) ($0.59) ($0.72) ($0.67) ($21.66) $12.41 ($0.99) ($0.19) ($0.05)
Weighted Average Basic Shares Outstanding		 173.17M 196.09M 205.52M 225.03M 246.35M 275.65M 7.96M 9.03M 10.44M 11.53M 11.57M
Diluted Earnings per Share		 ($0.49) ($0.46) ($0.37) ($0.59) ($0.72) ($0.67) ($21.66) $11.96 ($0.99) ($0.19) ($0.05)
Weighted Average Diluted Shares Outstanding		 173.17M 196.09M 205.52M 225.03M 246.35M 275.65M 7.96M 9.37M 10.44M 11.53M 11.57M

Quarterly Income Statements for TherapeuticsMD

This table shows TherapeuticsMD's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.38 -0.88 -0.73 -1.09 -0.61 0.25 -0.65 0.55 0.15 -0.62 0.10
Consolidated Net Income / (Loss)		 -3.38 -0.88 -0.73 -1.09 -0.61 0.25 -0.65 0.55 0.15 -0.62 0.10
Net Income / (Loss) Continuing Operations		 -1.43 -1.54 -0.81 -1.05 -0.57 0.11 -0.64 0.55 0.05 -0.61 0.10
Total Pre-Tax Income 		-1.43 -1.58 -0.81 -1.05 -0.57 0.08 -0.67 0.55 0.05 -0.58 0.10
Total Operating Income		 -1.77 -1.61 -1.14 -2.79 -1.13 -1.05 -1.28 -0.70 -0.86 -1.96 -0.72
Total Gross Profit		 -0.05 0.50 0.31 0.23 0.55 0.67 0.39 0.95 0.78 0.89 0.72
Total Revenue		 -0.05 0.50 0.31 0.23 0.55 0.67 0.39 0.95 0.78 0.89 0.72
Operating Revenue		 -0.05 0.50 0.31 0.23 0.55 0.67 0.39 0.95 0.78 0.89 0.72
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 1.72 2.11 1.46 3.02 1.68 1.71 1.67 1.65 1.65 2.86 1.45
Selling, General & Admin Expense		 1.59 1.48 1.32 1.58 1.59 1.61 1.49 1.55 1.52 2.70 1.35
Depreciation Expense		 0.13 0.64 0.13 0.18 0.10 0.10 0.10 0.10 0.10 0.10 0.09
Amortization Expense		 - - 0.00 0.00 0.00 - 0.09 0.00 0.03 - 0.00
Total Other Income / (Expense), net		 0.34 0.03 0.33 1.74 0.57 1.13 0.61 1.24 0.91 1.38 0.83
Interest & Investment Income		 - - - 0.35 0.28 - 0.03 0.38 0.53 - 0.04
Other Income / (Expense), net		 0.36 -0.09 0.33 1.40 0.30 1.61 0.58 0.87 0.38 2.14 0.79
Income Tax Expense		 0.00 -0.04 0.00 0.00 0.00 -0.03 -0.03 0.00 0.00 0.03 0.00
Net Income / (Loss) Discontinued Operations		 -1.94 0.66 0.08 -0.04 -0.04 0.14 -0.02 0.01 0.10 -0.01 -0.01
Basic Earnings per Share		 ($0.32) ($0.08) ($0.06) ($0.09) ($0.05) $0.01 ($0.06) $0.05 $0.01 ($0.05) $0.01
Weighted Average Basic Shares Outstanding		 10.70M 10.44M 11.53M 11.53M 11.53M 11.53M 11.55M 11.57M 11.57M 11.57M 11.57K
Diluted Earnings per Share		 ($0.32) ($0.08) ($0.06) ($0.09) ($0.05) $0.01 ($0.06) $0.05 $0.01 ($0.05) $0.01
Weighted Average Diluted Shares Outstanding		 10.70M 10.44M 11.53M 11.53M 11.53M 11.53M 11.55M 11.57M 11.57M 11.57M 11.64K
Weighted Average Basic & Diluted Shares Outstanding		 10.58M 11.53M 11.53M 11.53M 11.53M 0.00 - 11.57M 11.57M 0.00 11.57M

Annual Cash Flow Statements for TherapeuticsMD

This table details how cash moves in and out of TherapeuticsMD's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 13 67 -4.40 34 -0.78 -80 -88 -16 -45 0.73 2.42
Net Cash From Operating Activities		 -79 -69 -76 -107 -166 -159 -143 9.36 -23 1.17 2.45
Net Cash From Continuing Operating Activities		 -79 -69 -76 -107 -166 -159 -55 9.36 -23 1.17 2.45
Net Income / (Loss) Continuing Operations		 -85 -90 -77 -133 -176 -184 -79 1.07 -7.70 -2.31 -0.65
Consolidated Net Income / (Loss)		 -85 -90 -77 -133 -176 -184 -172 112 -10 -2.18 -0.57
Net Income / (Loss) Discontinued Operations		 - - - - - - -93 111 -2.58 0.13 0.08
Depreciation Expense		 0.03 0.08 0.14 0.18 1.39 4.07 0.74 1.19 0.92 0.51 0.38
Amortization Expense		 0.03 0.05 0.07 0.38 - - - - - 0.77 0.81
Non-Cash Adjustments To Reconcile Net Income		 7.21 20 6.89 8.88 22 22 18 11 1.27 1.53 0.25
Changes in Operating Assets and Liabilities, net		 -1.24 0.66 -6.34 16 -13 -1.80 5.31 -4.13 -18 0.67 1.66
Net Cash From Investing Activities		 -0.58 -1.26 -0.83 -21 -24 -1.60 -2.22 -0.36 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 -0.58 -1.26 -0.83 -21 -24 -1.60 -2.22 -0.36 0.00 0.00 0.00
Net Cash From Financing Activities		 93 137 73 163 189 81 130 -235 3.15 0.00 0.00
Net Cash From Continuing Financing Activities		 93 137 73 163 189 81 130 -235 3.15 0.00 0.00
Other Net Changes in Cash		 - - - - - - - 210 -25 -0.44 -0.03

Quarterly Cash Flow Statements for TherapeuticsMD

This table details how cash moves in and out of TherapeuticsMD's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -3.56 -5.84 0.01 0.89 -0.19 0.01 0.69 0.34 1.05 0.37 0.94
Net Cash From Operating Activities		 -6.03 -4.96 -0.23 1.45 -0.07 0.02 0.69 0.39 1.00 0.38 0.94
Net Cash From Continuing Operating Activities		 -6.03 -4.96 -0.23 1.45 -0.07 0.02 0.70 0.38 1.00 0.38 0.94
Net Income / (Loss) Continuing Operations		 -1.43 -1.54 -0.81 -1.05 -0.57 0.11 -0.64 0.55 0.05 -0.61 0.10
Consolidated Net Income / (Loss)		 -3.38 -0.88 -0.73 -1.09 -0.61 0.25 -0.65 0.55 0.15 -0.62 0.10
Net Income / (Loss) Discontinued Operations		 -1.94 0.66 0.08 -0.04 -0.04 0.14 -0.02 0.01 0.10 -0.01 -0.01
Depreciation Expense		 0.13 0.64 0.13 0.18 0.10 0.10 0.10 0.10 0.10 0.10 0.09
Amortization Expense		 - - - - - - 0.15 - - - 0.23
Non-Cash Adjustments To Reconcile Net Income		 0.18 0.12 0.11 1.36 0.03 0.03 0.11 0.00 0.03 0.11 0.00
Changes in Operating Assets and Liabilities, net		 -4.96 -4.11 0.34 0.97 0.37 -1.00 0.98 -0.26 0.82 -0.03 0.51
Net Cash From Discontinued Operating Activities		 - - - - - - -0.01 - - - -0.01
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 -0.00 2.00 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Financing Activities		 -0.00 2.00 0.00 - - - 0.00 - - - 0.00
Other Net Changes in Cash		 2.47 -2.88 0.24 -0.56 -0.11 -0.01 -0.01 -0.06 0.05 -0.01 -0.01

Annual Balance Sheets for TherapeuticsMD

This table presents TherapeuticsMD's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 74 142 143 212 266 182 169 90 43 39 38
Total Current Assets		 71 139 140 187 208 128 119 55 12 12 14
Cash & Equivalents		 65 132 127 162 161 80 65 38 4.33 5.06 7.48
Prepaid Expenses		 2.23 2.30 6.60 11 11 7.54 5.86 6.03 4.04 3.64 3.44
Other Current Assets		 - - - - - - 0.00 - 3.09 20 3.53
Plant, Property, & Equipment, net		 0.20 0.52 0.44 0.47 2.51 1.94 0.82 0.08 0.00 0.00 0.00
Total Noncurrent Assets		 2.85 2.55 3.24 25 55 51 49 35 32 11 23
Intangible Assets		 1.62 2.41 3.10 4.09 5.26 41 7.14 6.94 6.10 4.32 3.76
Other Noncurrent Operating Assets		 1.23 0.14 0.14 21 50 9.82 8.49 28 25 6.23 19
Total Liabilities & Shareholders' Equity		 74 142 143 212 266 182 169 90 43 39 38
Total Liabilities		 11 15 13 114 257 306 263 55 14 11 11
Total Current Liabilities		 11 15 13 41 53 59 253 47 6.85 5.17 4.79
Accounts Payable		 3.13 7.36 4.10 23 19 21 3.37 21 0.03 0.26 0.38
Accrued Expenses		 - - 9.22 - - 38 - - 3.13 2.13 1.74
Other Current Nonoperating Liabilities		 - - - - - - 48 26 3.69 2.78 2.67
Total Noncurrent Liabilities		 0.00 0.00 0.00 73 204 246 10 8.48 7.17 6.29 6.00
Capital Lease Obligations		 - - - - - 8.68 - - - - 5.12
Other Noncurrent Operating Liabilities		 - - - 0.00 9.15 0.00 10 1.11 7.17 6.29 0.87
Commitments & Contingencies		 - - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 63 127 130 98 9.20 -124 -94 35 29 27 27
Total Preferred & Common Equity		 63 127 130 98 9.20 -124 -94 35 29 27 27
Total Common Equity		 63 127 130 98 9.20 -124 -94 35 29 27 27
Common Stock		 283 437 517 617 705 755 958 975 979 979 979
Retained Earnings		 -220 -310 -387 -519 -695 -879 -1,051 -939 -950 -952 -952

Quarterly Balance Sheets for TherapeuticsMD

This table presents TherapeuticsMD's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 50 42 40 40 38 39 39 38
Total Current Assets		 17 12 12 12 13 13 15 15
Cash & Equivalents		 10 4.34 5.23 5.05 5.75 6.07 7.12 8.42
Prepaid Expenses		 4.57 3.87 3.68 3.78 3.77 3.65 3.72 3.63
Other Current Assets		 2.71 3.22 2.91 3.32 3.00 3.74 3.67 3.21
Plant, Property, & Equipment, net		 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 33 31 28 27 26 25 24 22
Intangible Assets		 6.66 5.97 4.52 4.43 4.14 4.04 3.91 3.67
Other Noncurrent Operating Assets		 26 25 24 23 22 21 20 19
Total Liabilities & Shareholders' Equity		 50 42 40 40 38 39 39 38
Total Liabilities		 22 13 12 12 11 11 11 11
Total Current Liabilities		 15 6.47 5.82 5.98 4.74 4.66 4.95 4.91
Accounts Payable		 0.70 2.86 2.82 3.05 0.18 0.35 0.26 0.02
Accrued Expenses		 - - - - 1.78 1.59 2.02 2.23
Other Current Nonoperating Liabilities		 6.89 3.61 3.00 2.92 2.79 2.72 2.67 2.67
Total Noncurrent Liabilities		 7.93 6.96 6.64 6.48 6.76 6.55 6.28 5.70
Capital Lease Obligations		 - - - - - - - 4.82
Other Noncurrent Operating Liabilities		 7.93 0.64 0.64 6.48 6.76 6.55 6.28 0.87
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 28 29 28 27 27 27 27 27
Total Preferred & Common Equity		 28 29 28 27 27 27 27 27
Total Common Equity		 28 29 28 27 27 27 27 27
Common Stock		 977 979 979 979 979 979 979 979
Retained Earnings		 -949 -950 -951 -952 -952 -952 -952 -952

Annual Metrics And Ratios for TherapeuticsMD

This table displays calculated financial ratios and metrics derived from TherapeuticsMD's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 177,848,041.00 196,580,212.00 216,429,642.00 237,881,189.00 271,177,076.00 272,812,271.00 424,928,670.00 9,467,104.00 10,575,240.00 10,575,240.00 10,575,240.00
DEI Adjusted Shares Outstanding		 3,556,961.00 3,931,604.00 4,328,593.00 4,757,624.00 5,423,542.00 5,456,245.00 8,498,573.00 9,467,104.00 10,575,240.00 10,575,240.00 10,575,240.00
DEI Earnings Per Adjusted Shares Outstanding		 -23.92 -22.86 -17.77 -27.87 -32.48 -33.64 -20.29 11.83 -0.97 -0.21 -0.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 34.05% -3.90% -13.32% -4.04% 208.38% 30.67% -96.03% 2,619.12% -98.14% 35.25% 71.61%
EBITDA Growth		 -57.64% -5.55% 14.52% -66.03% -15.65% -2.42% 47.92% 103.03% -386.07% 82.43% 133.22%
EBIT Growth		 -56.84% -5.63% 14.41% -66.30% -16.23% -4.19% 48.82% 101.50% -750.04% 67.99% 67.92%
NOPAT Growth		 -57.64% -5.94% 13.99% -67.75% -16.11% -2.87% 48.84% 102.14% -600.93% 28.29% 28.17%
Net Income Growth		 -56.92% -5.64% 14.41% -72.40% -32.82% -4.19% 6.05% 164.96% -109.18% 78.78% 73.91%
EPS Growth		 -36.11% 6.12% 19.57% -59.46% -22.03% 6.94% 6.05% 155.22% -108.28% 80.81% 73.68%
Operating Cash Flow Growth		 -73.64% 12.53% -10.14% -40.25% -55.15% 3.77% 10.52% 106.56% -346.62% 105.07% 109.74%
Free Cash Flow Firm Growth		 -77.48% 0.31% -0.63% -59.71% -42.88% 22.79% 91.45% -143.39% 32.03% 93.05% -386.89%
Invested Capital Growth		 44.72% -146.15% 168.56% 235.08% 362.83% -2.60% -110.98% 513.61% 48.80% -11.37% 8.33%
Revenue Q/Q Growth		 7.31% -5.57% -2.12% 6.38% 27.84% 66.96% -97.67% 208.80% -98.12% 10.34% 8.08%
EBITDA Q/Q Growth		 -1.38% -6.32% 1.62% -13.91% -4.44% 9.17% 41.62% 113.35% -116.19% 67.58% 261.82%
EBIT Q/Q Growth		 -1.39% -6.35% 1.61% -14.01% -4.55% 5.66% 42.78% 105.28% -118.64% 47.73% -187.00%
NOPAT Q/Q Growth		 -1.42% -6.40% 1.60% -14.45% -4.33% 5.92% 42.74% 105.31% -114.37% 8.45% 80.17%
Net Income Q/Q Growth		 -1.41% -6.33% 1.80% -15.67% -6.05% 3.85% -0.51% 1,392.52% -115.05% 34.23% -288.41%
EPS Q/Q Growth		 3.92% -4.55% 5.13% -15.69% -4.35% 12.99% -0.51% 1,372.34% -115.52% 34.48% -600.00%
Operating Cash Flow Q/Q Growth		 -1.70% 1.41% -7.31% -7.38% -15.85% 11.37% -6.89% 115.49% -290.52% 130.73% 17.08%
Free Cash Flow Firm Q/Q Growth		 -3.98% 1.60% -6.19% -1.82% -37.12% 22.65% 88.54% -1,174.99% -191.01% 78.23% 61.82%
Invested Capital Q/Q Growth		 53.93% -242.85% 132.67% -46.83% 141.58% 1.21% -118.75% 0.00% 14.27% 0.48% 18.20%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 77.63% 78.38% 84.28% 83.00% 87.24% 75.37% 45.51% 98.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -422.14% -463.69% -457.27% -791.18% -296.72% -232.57% -3,053.60% 3.41% -523.81% -68.03% 13.17%
Operating Margin		 -422.93% -466.27% -462.69% -808.85% -304.56% -239.77% -3,092.77% 1.70% -654.61% -347.08% -145.27%
EBIT Margin		 -422.45% -464.37% -458.54% -794.68% -299.52% -238.84% -3,082.20% 1.70% -594.62% -140.72% -26.31%
Profit (Net Income) Margin		 -422.37% -464.32% -458.50% -823.74% -354.79% -282.90% -6,700.93% 160.08% -789.40% -123.85% -18.83%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 217.41% 10,428.03% 132.76% 93.09% 87.14%
Interest Burden Percent		 99.98% 99.99% 99.99% 103.66% 118.45% 118.45% 100.00% 90.18% 100.00% 94.55% 82.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -1,511.03% -404.77% -256.51% -298.79% 16.51% -25.21% -16.02% -11.76%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -1,472.53% -146.44% -331.27% -390.36% 320.49% 25.24% -144.90% -265.71%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 1,394.41% 74.68% 576.24% 457.25% -399.55% -6.70% 8.32% 9.66%
Return on Equity (ROE)		 -152.67% -94.33% -59.77% -116.62% -330.09% 319.73% 158.45% -383.04% -31.90% -7.70% -2.10%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -2,205.41% -1,619.10% -533.70% -253.87% 0.00% -117.92% -64.43% -3.97% -19.75%
Operating Return on Assets (OROA)		 -128.15% -83.15% -53.86% -72.04% -62.22% -69.23% -45.18% 0.92% -11.58% -6.03% -2.08%
Return on Assets (ROA)		 -128.12% -83.14% -53.85% -74.67% -73.71% -82.00% -98.22% 86.17% -15.37% -5.31% -1.49%
Return on Common Equity (ROCE)		 -152.67% -94.33% -59.77% -116.62% -330.09% 319.73% 158.45% -383.04% -31.90% -7.70% -2.10%
Return on Equity Simple (ROE_SIMPLE)		 -134.91% -70.50% -59.21% -135.98% -1,914.39% 148.00% 184.16% 318.69% -35.09% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -60 -63 -54 -91 -106 -109 -56 1.19 -5.97 -4.28 -3.07
NOPAT Margin		 -296.05% -326.39% -323.88% -566.19% -213.19% -167.84% -2,164.94% 1.70% -458.23% -242.95% -101.69%
Net Nonoperating Expense Percent (NNEP)		 -43.84% -27.21% -17.46% -38.50% -258.33% 74.76% 91.57% -303.98% -50.45% 128.87% 253.96%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -20.37% -15.63% -9.60%
Cost of Revenue to Revenue		 22.37% 21.62% 15.72% 17.00% 12.76% 24.63% 54.49% 2.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 142.59% 265.28% 343.93% 720.45% 121.85% 118.62% 3,138.28% 81.06% 683.79% 346.17% 226.74%
R&D to Revenue		 357.66% 278.68% 201.77% 169.57% 39.87% 16.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 500.56% 544.65% 546.97% 891.84% 391.80% 315.14% 3,138.28% 96.30% 754.61% 447.08% 245.27%
Earnings before Interest and Taxes (EBIT)		 -85 -90 -77 -128 -149 -155 -79 1.19 -7.74 -2.48 -0.80
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -85 -90 -77 -127 -147 -151 -79 2.38 -6.82 -1.20 0.40
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 28.48 8.87 9.56 8.79 64.79 0.00 0.00 1.49 0.80 0.36 0.70
Price to Tangible Book Value (P/TBV)		 29.23 9.05 9.79 9.18 151.20 0.00 0.00 1.86 1.01 0.43 0.82
Price to Revenue (P/Rev)		 89.15 58.45 73.99 53.25 12.01 5.14 54.99 0.75 18.04 5.63 6.24
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.47 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 213.91% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 401.80 82.77 14.65 11.92 0.00 0.16 0.68 0.19 0.61
Enterprise Value to Revenue (EV/Rev)		 85.94 51.66 66.41 47.77 12.69 7.70 102.93 0.04 14.72 2.76 5.46
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.27 0.00 0.00 41.45
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.55 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.55 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.32 0.00 4.15 6.72
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.75 21.15 -1.99 -2.01 0.00 0.00 0.00 0.19
Long-Term Debt to Equity		 0.00 0.00 0.00 0.75 21.15 -1.99 0.00 0.00 0.00 0.00 0.19
Financial Leverage		 -1.04 -1.03 -1.00 -0.95 -0.51 -1.74 -1.17 -1.25 -0.27 -0.06 -0.04
Leverage Ratio		 1.19 1.13 1.11 1.56 4.48 -3.90 -1.61 -4.44 2.08 1.45 1.41
Compound Leverage Factor		 1.19 1.13 1.11 1.62 5.30 -4.62 -1.61 -4.01 2.08 1.37 1.16
Debt to Total Capital		 0.00% 0.00% 0.00% 42.94% 95.49% 201.33% 198.91% 0.00% 0.00% 0.00% 16.01%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 198.91% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 42.94% 95.49% 201.33% 0.00% 0.00% 0.00% 0.00% 16.01%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 57.06% 4.51% -101.33% -98.91% 100.00% 100.00% 100.00% 83.99%
Debt to EBITDA		 0.00 0.00 0.00 -0.58 -1.32 -1.63 -2.40 0.00 0.00 0.00 12.87
Net Debt to EBITDA		 0.00 0.00 0.00 0.69 -0.23 -1.10 -1.57 0.00 0.00 0.00 -5.93
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.58 -1.32 -1.63 0.00 0.00 0.00 0.00 12.87
Debt to NOPAT		 0.00 0.00 0.00 -0.81 -1.84 -2.26 -3.38 0.00 0.00 0.00 -1.67
Net Debt to NOPAT		 0.00 0.00 0.00 0.97 -0.32 -1.52 -2.21 0.00 0.00 0.00 0.77
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.81 -1.84 -2.26 0.00 0.00 0.00 0.00 -1.67
Altman Z-Score		 94.29 41.37 51.53 -0.03 -3.22 -8.12 -10.84 -13.04 -30.12 -33.75 -34.04
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.63 9.30 10.48 4.55 3.93 2.17 0.47 1.18 1.72 2.37 3.02
Quick Ratio		 6.35 9.08 9.87 4.20 3.49 1.91 0.26 0.81 0.63 0.98 1.56
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -61 -61 -61 -98 -140 -108 -9.22 -22 -15 -1.06 -5.16
Operating Cash Flow to CapEx		 -47,831.03% -17,453.40% -123,195.26% -49,212.95% -6,764.00% -77,039.13% -419,685.29% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -20.88 -5.09 -3.77 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -22.83 -6.04 -5.58 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -22.88 -6.13 -5.59 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.30 0.18 0.12 0.09 0.21 0.29 0.01 0.54 0.02 0.04 0.08
Accounts Receivable Turnover		 7.74 5.13 3.80 2.09 2.80 2.29 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 4.81 4.74 2.06 1.15 0.84 1.61 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 153.83 54.11 35.18 35.39 33.32 29.16 1.86 155.30 0.00 0.00 0.00
Accounts Payable Turnover		 0.95 0.80 0.46 0.20 0.30 0.79 0.11 0.11 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 47.15 71.19 96.04 174.49 130.35 159.73 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 75.82 77.02 177.29 316.85 435.82 226.81 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 382.82 457.14 792.87 1,789.33 1,207.79 459.81 3,181.51 3,185.06 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -259.85 -308.93 -519.53 -1,297.99 -641.62 -73.27 -3,181.51 -3,185.06 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.64 -4.04 2.77 9.29 43 42 -4.60 19 28 25 27
Invested Capital Turnover		 -8.73 -6.81 -26.39 2.67 1.90 1.53 0.14 9.70 0.06 0.07 0.12
Increase / (Decrease) in Invested Capital		 1.33 -2.40 6.82 6.52 34 -1.12 -46 24 9.28 -3.22 2.09
Enterprise Value (EV)		 1,731 1,000 1,114 769 630 499 265 3.04 19 4.86 16
Market Capitalization		 1,796 1,131 1,241 857 596 334 141 52 23 9.92 19
Book Value per Share		 $0.35 $0.65 $0.60 $0.41 $0.03 ($0.45) ($0.22) $3.73 $2.77 $2.37 $2.32
Tangible Book Value per Share		 $0.35 $0.64 $0.59 $0.39 $0.01 ($0.61) ($0.24) $2.99 $2.19 $2.00 $2.00
Total Capital		 63 127 130 171 204 122 95 35 29 27 32
Total Debt		 0.00 0.00 0.00 73 195 246 188 0.00 0.00 0.00 5.12
Total Long-Term Debt		 0.00 0.00 0.00 73 195 246 0.00 0.00 0.00 0.00 5.12
Net Debt		 -65 -132 -127 -88 34 166 123 -49 -4.33 -5.06 -2.36
Capital Expenditures (CapEx)		 0.17 0.40 0.06 0.22 2.45 0.21 0.03 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.69 -7.11 -0.90 -16 -5.42 -11 -10 -41 0.62 2.03 2.18
Debt-free Net Working Capital (DFNWC)		 60 124 126 146 155 69 55 8.51 4.94 7.09 9.66
Net Working Capital (NWC)		 60 124 126 146 155 69 -133 8.51 4.94 7.09 9.66
Net Nonoperating Expense (NNE)		 25 27 23 41 70 75 117 -111 4.31 -2.10 -2.50
Net Nonoperating Obligations (NNO)		 -65 -132 -127 -88 34 166 89 -16 -0.98 -2.28 0.31
Total Depreciation and Amortization (D&A)		 0.06 0.13 0.21 0.56 1.39 4.07 0.74 1.19 0.92 1.28 1.19
Debt-free, Cash-free Net Working Capital to Revenue		 -23.29% -36.71% -5.38% -98.84% -10.91% -17.45% -391.02% -58.32% 47.24% 115.50% 72.04%
Debt-free Net Working Capital to Revenue		 297.94% 642.82% 752.38% 905.00% 313.03% 106.62% 2,131.60% 12.17% 379.57% 402.78% 319.66%
Net Working Capital to Revenue		 297.94% 642.82% 752.38% 905.00% 313.03% 106.62% -5,185.50% 12.17% 379.57% 402.78% 319.66%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($24.50) ($23.00) ($18.50) ($29.50) ($36.00) ($33.50) ($21.50) $12.41 ($0.98) ($0.19) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 3.92M 3.95M 4.33M 4.82M 5.43M 7.76M 8.67M 9.03M 10.44M 11.53M 11.57M
Adjusted Diluted Earnings per Share		 ($24.50) ($23.00) ($18.50) ($29.50) ($36.00) ($33.50) ($21.50) $11.96 ($0.98) ($0.19) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 3.92M 3.95M 4.33M 4.82M 5.43M 7.76M 8.67M 9.37M 10.44M 11.53M 11.57M
Adjusted Basic & Diluted Earnings per Share		 ($24.50) ($23.00) ($18.50) ($29.50) ($36.00) ($33.50) ($21.50) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.46M 3.92M 4.11M 4.50M 4.93M 5.51M 7.96M 0.00 11.53M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -60 -63 -54 -91 -106 -109 -56 7.46 -5.97 -3.39 -2.95
Normalized NOPAT Margin		 -296.05% -326.39% -323.88% -566.19% -213.19% -167.84% -2,164.94% 10.67% -458.23% -192.55% -97.61%
Pre Tax Income Margin		 -422.37% -464.32% -458.50% -823.74% -354.79% -282.90% -3,082.20% 1.54% -594.62% -133.05% -21.61%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -27.35 -5.42 -5.42 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -19.49 -3.86 -3.81 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -27.40 -5.51 -5.43 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -19.53 -3.95 -3.82 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for TherapeuticsMD

This table displays calculated financial ratios and metrics derived from TherapeuticsMD's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00
DEI Adjusted Shares Outstanding		 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00 10,575,240.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.32 -0.08 -0.07 -0.10 -0.06 0.02 -0.06 0.05 0.01 -0.06 0.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -114.97% -99.27% -24.76% -46.45% 1,132.08% 32.87% 25.56% 306.84% 43.33% 33.88% 84.22%
EBITDA Growth		 91.05% -102.18% 69.73% 45.80% 42.18% 162.52% 33.73% 121.99% 48.18% -58.13% 186.38%
EBIT Growth		 90.34% -103.51% 64.20% 41.16% 40.66% 133.20% 13.84% 112.27% 42.67% -67.91% 108.90%
NOPAT Growth		 87.79% -102.33% 57.18% -12.82% 36.04% -27.52% -12.17% 64.40% -8.59% 4.50% 19.37%
Net Income Growth		 88.34% -101.14% 79.63% 54.85% 81.97% 128.54% 11.04% 150.55% 124.96% -345.63% 114.55%
EPS Growth		 89.78% -100.93% 0.00% 0.00% 84.38% 112.50% 0.00% 155.56% 120.00% -600.00% 116.67%
Operating Cash Flow Growth		 -134.03% -116.40% 97.37% 142.84% 98.82% 100.34% 399.56% -72.88% 1,507.04% 2,105.88% 36.44%
Free Cash Flow Firm Growth		 -280.99% -141.96% -242.00% -201.59% 96.19% 117.10% 154.09% 145.92% 212.33% -294.58% -131.51%
Invested Capital Growth		 0.00% 48.80% 96.03% 69.15% 0.80% -11.37% -30.39% -23.83% -7.91% 8.33% 9.52%
Revenue Q/Q Growth		 -112.13% 1,047.17% -37.65% -25.24% 133.76% 21.94% -41.08% 142.24% -17.65% 13.90% -18.93%
EBITDA Q/Q Growth		 42.63% 17.35% 36.35% -79.59% 38.80% 189.37% -167.47% 146.76% -244.19% 172.21% 39.21%
EBIT Q/Q Growth		 40.31% -20.16% 52.38% -72.31% 39.81% 167.22% -223.58% 125.68% -381.29% 137.63% -65.75%
NOPAT Q/Q Growth		 28.28% 9.14% 29.11% -144.22% 59.34% -81.16% 37.64% -13.99% -24.03% -59.33% 47.36%
Net Income Q/Q Growth		 -39.93% 73.86% 16.87% -48.50% 44.13% 141.38% -359.13% 184.38% -72.41% -507.24% 115.35%
EPS Q/Q Growth		 0.00% 75.00% 25.00% -50.00% 44.44% 120.00% -700.00% 183.33% -80.00% -600.00% 120.00%
Operating Cash Flow Q/Q Growth		 -77.71% 17.72% 95.38% 734.50% -104.89% 123.94% 3,935.29% -42.57% 153.55% -62.46% 149.60%
Free Cash Flow Firm Q/Q Growth		 -278.52% 59.98% -68.40% 15.57% 93.31% 279.65% 432.78% -30.42% -83.63% -411.18% 13.73%
Invested Capital Q/Q Growth		 33.29% 14.27% 20.66% -7.97% -20.57% 0.48% -5.23% 0.69% -3.96% 18.20% -4.18%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -211.55% -215.97% -518.80% -135.83% 99.55% -113.99% 28.05% -49.11% 31.13% 53.45%
Operating Margin		 0.00% -320.92% -364.86% -1,191.88% -207.31% -156.97% -325.95% -73.00% -109.95% -219.71% -99.86%
EBIT Margin		 0.00% -338.45% -258.47% -595.73% -153.38% 84.56% -177.35% 17.96% -61.35% 20.27% 8.56%
Profit (Net Income) Margin		 0.00% -175.90% -234.50% -465.81% -111.33% 37.78% -166.16% 57.88% 19.39% -69.32% 13.12%
Tax Burden Percent		 235.56% 55.74% 90.73% 103.81% 107.41% 303.61% 97.75% 101.10% 304.00% 106.72% 92.23%
Interest Burden Percent		 101.41% 93.23% 100.00% 75.32% 67.58% 14.72% 95.84% 318.71% -10.40% -320.44% 166.13%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% -37.35% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -12.36% -11.87% -33.22% -9.31% -14.22% -14.50% -6.75% -12.82% -17.78% -13.44%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -15.22% -13.31% -52.73% -16.16% -118.06% 4.72% 585.18% -43.68% -94.29% -55.52%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 4.04% 2.00% 7.92% 1.58% 6.78% 0.22% 4.48% 5.26% 3.43% 4.02%
Return on Equity (ROE)		 0.00% -8.32% -9.88% -25.30% -7.73% -7.44% -14.28% -2.26% -7.56% -14.35% -9.42%
Cash Return on Invested Capital (CROIC)		 135.27% -64.43% -83.87% -71.86% -19.58% -3.97% 20.73% 21.00% -56.38% -19.75% -20.30%
Operating Return on Assets (OROA)		 0.00% -6.59% -6.10% -12.65% -5.44% 3.63% -8.13% 1.17% -4.39% 1.60% 0.76%
Return on Assets (ROA)		 0.00% -3.42% -5.53% -9.89% -3.95% 1.62% -7.62% 3.77% 1.39% -5.48% 1.16%
Return on Common Equity (ROCE)		 0.00% -8.32% -9.88% -25.30% -7.73% -7.44% -14.28% -2.26% -7.56% -14.35% -9.42%
Return on Equity Simple (ROE_SIMPLE)		 243.50% 0.00% -25.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.24 -1.13 -0.80 -1.95 -0.79 -1.44 -0.90 -0.70 -0.86 -1.37 -0.72
NOPAT Margin		 0.00% -224.64% -255.40% -834.32% -145.12% -215.60% -228.17% -73.00% -109.95% -153.80% -99.86%
Net Nonoperating Expense Percent (NNEP)		 -130.38% 2.86% 1.44% 19.50% 6.84% 103.84% -19.22% -591.92% 30.86% 76.51% 42.08%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.85% -2.79% -7.06% -2.93% -5.25% -3.35% -2.55% -3.14% -4.29% -2.27%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 294.02% 422.36% 676.07% 289.76% 240.93% 379.39% 162.92% 193.62% 302.58% 186.88%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 420.92% 464.86% 1,291.88% 307.31% 256.97% 425.95% 173.00% 209.95% 319.71% 199.86%
Earnings before Interest and Taxes (EBIT)		 -1.41 -1.70 -0.81 -1.39 -0.84 0.56 -0.70 0.17 -0.48 0.18 0.06
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.29 -1.06 -0.68 -1.21 -0.74 0.66 -0.45 0.27 -0.39 0.28 0.39
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.15 0.80 0.92 0.67 0.71 0.36 0.40 0.49 0.45 0.70 0.00
Price to Tangible Book Value (P/TBV)		 1.51 1.01 1.16 0.80 0.84 0.43 0.47 0.58 0.53 0.82 0.00
Price to Revenue (P/Rev)		 0.47 18.04 22.03 18.64 11.99 5.63 5.80 5.25 4.45 6.24 0.01
Price to Earnings (P/E)		 0.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 41.20 0.00 0.13
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 211.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.43% 0.00% 761.29%
Enterprise Value to Invested Capital (EV/IC)		 0.89 0.68 0.65 0.42 0.56 0.19 0.21 0.31 0.23 0.61 0.00
Enterprise Value to Revenue (EV/Rev)		 0.32 14.72 18.41 13.39 8.83 2.76 2.68 2.87 1.91 5.46 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48.43 41.45 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 1.83 0.00 0.00 0.00 0.00 4.15 2.37 7.17 2.54 6.72 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 1.32 0.00 0.00 0.00 0.00 0.00 0.82 1.26 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.18
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.18
Financial Leverage		 -0.12 -0.27 -0.15 -0.15 -0.10 -0.06 0.05 0.01 -0.12 -0.04 -0.07
Leverage Ratio		 1.80 2.08 1.68 1.59 1.63 1.45 1.45 1.43 1.43 1.41 1.41
Compound Leverage Factor		 1.83 1.94 1.68 1.20 1.10 0.21 1.39 4.56 -0.15 -4.52 2.34
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.01% 15.17%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.01% 15.17%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 83.99% 84.83%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.87 3.91
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.93 -2.92
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.87 3.91
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.67 -1.73
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.77 1.29
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.67 -1.73
Altman Z-Score		 -24.09 -29.66 -30.32 -32.21 -32.62 -33.49 -34.09 -33.54 -33.46 -33.96 -35.05
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.20 1.72 1.78 2.03 2.03 2.37 2.64 2.89 2.93 3.02 3.11
Quick Ratio		 0.70 0.63 0.67 0.90 0.84 0.98 1.21 1.30 1.44 1.56 1.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -26 -10 -18 -15 -0.99 1.78 9.48 6.80 1.11 -3.46 -2.99
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -1,300.76 0.00 0.00 -2,960.86 -330.27 0.00 0.00 3,399.00 371.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -301.40 0.00 0.00 290.60 -23.67 0.00 0.00 197.00 333.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -301.40 0.00 0.00 290.60 -23.67 0.00 0.00 197.00 333.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.37 0.02 0.02 0.02 0.04 0.04 0.05 0.07 0.07 0.08 0.09
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3,650.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 25 28 34 31 25 25 24 24 23 27 26
Invested Capital Turnover		 5.60 0.06 0.05 0.04 0.06 0.07 0.06 0.09 0.12 0.12 0.13
Increase / (Decrease) in Invested Capital		 25 9.28 17 13 0.20 -3.22 -10 -7.49 -1.98 2.09 2.27
Enterprise Value (EV)		 22 19 22 13 14 4.86 4.94 7.36 5.33 16 -3.57
Market Capitalization		 32 23 26 19 19 9.92 11 13 12 19 0.02
Book Value per Share		 $2.65 $2.77 $2.49 $2.40 $2.35 $2.37 $2.31 $2.36 $2.37 $2.32 $2,330.48
Tangible Book Value per Share		 $2.02 $2.19 $1.97 $2.01 $1.97 $2.00 $1.96 $2.01 $2.03 $2.00 $2,013.65
Total Capital		 28 29 29 28 27 27 27 27 27 32 32
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.12 4.82
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.12 4.82
Net Debt		 -10 -4.33 -4.34 -5.23 -5.05 -5.06 -5.75 -6.07 -7.12 -2.36 -3.60
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.24 0.62 0.72 0.78 1.13 2.03 2.03 2.73 2.44 2.18 1.93
Debt-free Net Working Capital (DFNWC)		 2.93 4.94 5.06 6.01 6.18 7.09 7.77 8.80 9.56 9.66 10
Net Working Capital (NWC)		 2.93 4.94 5.06 6.01 6.18 7.09 7.77 8.80 9.56 9.66 10
Net Nonoperating Expense (NNE)		 2.14 -0.24 -0.07 -0.86 -0.18 -1.69 -0.24 -1.25 -1.01 -0.75 -0.82
Net Nonoperating Obligations (NNO)		 -3.28 -0.98 5.50 3.77 -2.12 -2.28 -2.96 -3.35 -4.45 0.31 -0.93
Total Depreciation and Amortization (D&A)		 0.13 0.64 0.13 0.18 0.10 0.10 0.25 0.10 0.10 0.10 0.33
Debt-free, Cash-free Net Working Capital to Revenue		 -10.43% 47.24% 59.80% 77.91% 70.86% 115.50% 110.05% 106.68% 87.37% 72.04% 57.65%
Debt-free Net Working Capital to Revenue		 4.22% 379.57% 421.60% 603.21% 387.09% 402.78% 422.11% 343.85% 341.85% 319.66% 308.74%
Net Working Capital to Revenue		 4.22% 379.57% 421.60% 603.21% 387.09% 402.78% 422.11% 343.85% 341.85% 319.66% 308.74%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.32) ($0.08) ($0.06) ($0.09) ($0.05) $0.01 ($0.06) $0.05 $0.01 ($0.05) $0.01
Adjusted Weighted Average Basic Shares Outstanding		 10.70M 10.44M 11.53M 11.53M 11.53M 11.53M 11.55M 11.57M 11.57M 11.57M 11.57K
Adjusted Diluted Earnings per Share		 ($0.32) ($0.08) $0.00 $0.00 ($0.05) $0.01 ($0.06) $0.05 $0.01 ($0.05) $0.01
Adjusted Weighted Average Diluted Shares Outstanding		 10.70M 10.44M 11.53M 11.53M 11.53M 11.53M 11.55M 11.57M 11.57M 11.57M 11.64K
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.08) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 10.58M 11.53M 11.53M 11.53M 0.00 0.00 0.00 0.00 0.00 0.00 11.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.24 -1.13 -0.80 -1.07 -0.79 -0.73 -0.90 -0.49 -0.60 -1.37 -0.51
Normalized NOPAT Margin		 0.00% -224.64% -255.40% -457.09% -145.12% -109.88% -228.17% -51.10% -76.96% -153.80% -69.90%
Pre Tax Income Margin		 0.00% -315.54% -258.47% -448.72% -103.66% 12.44% -169.97% 57.25% 6.38% -64.95% 14.23%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -70.70 0.00 0.00 -278.80 -279.67 0.00 0.00 85.50 -160.33 0.00 0.00
NOPAT to Interest Expense		 -62.06 0.00 0.00 -390.46 -264.60 0.00 0.00 -347.50 -287.33 0.00 0.00
EBIT Less CapEx to Interest Expense		 -70.70 0.00 0.00 -278.80 -279.67 0.00 0.00 85.50 -160.33 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -62.06 0.00 0.00 -390.46 -264.60 0.00 0.00 -347.50 -287.33 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

TherapeuticsMD Financials - Frequently Asked Questions

According to the most recent income statement we have on file, TherapeuticsMD's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

TherapeuticsMD's net income appears to be on a downward trend, with a most recent value of -$569 thousand in 2025, falling from -$85.08 million in 2015. The previous period was -$2.18 million in 2024. Check out TherapeuticsMD's forecast to explore projected trends and price targets.

TherapeuticsMD's total operating income in 2025 was -$4.39 million, based on the following breakdown:
  • Total Gross Profit: $3.02 million
  • Total Operating Expenses: $7.41 million

Over the last 10 years, TherapeuticsMD's total revenue changed from $20.14 million in 2015 to $3.02 million in 2025, a change of -85.0%.

TherapeuticsMD's total liabilities were at $10.78 million at the end of 2025, a 5.9% decrease from 2024, and a 1.1% increase since 2015.

In the past 10 years, TherapeuticsMD's cash and equivalents has ranged from $4.33 million in 2023 to $161.61 million in 2018, and is currently $7.48 million as of their latest financial filing in 2025.

Over the last 10 years, TherapeuticsMD's book value per share changed from 0.35 in 2015 to 2.32 in 2025, a change of 555.1%.


Related Companies

Financial statements for NASDAQ:TXMD last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel